Vatican and Biotech Company Hold Conference to Promote Adult Stem Cell Research
This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on January 1, 2003. The length of the article is 564 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: PharmaGap patents new method to grow skin stem cells.
Publication: BIOTECH Patent News
Rating: 
(out of reviews)
List Price: $ 5.95
Price: $ 5.95
This digital document is an article from First Things: A Monthly Journal of Religion and Public Life, published by Institute on Religion and Public Life on January 1, 2002. The length of the article is 3547 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Rating: List Price: $ 5.95 Price: $ 5.95
Find More “stem Cell Article ” Products
Citation Details
Title: The basics about stem cells. (out of reviews)
International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich. International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, (a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists. The company’s management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline’s products are distributed in the United States and Europe. www.ellismartinreport.com http contact: martinreports@gmail.com International Stem Cell is a paid sponsor of The Ellis Martin Report
Shirdesh has Retinopathy of Prematurity (ROP) and came to China for adult stem cell therapy. He received several transplants of non-embryonic umbilical cord blood blood stem cells. Therapy was delivered by the medical staff at Bethune International Peace Hospital. International patient services were provided by Beike Biotech.
This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on September 1, 2003. The length of the article is 465 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: StemCells grants license to StemCell Technologies to studyneural stem cells.
Publica
Rating: (out of reviews)
List Price: $ 5.95
Price: $ 5.95
This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on June 1, 2009. The length of the article is 539 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details
Title: NeoStem files patent application for cosmetic stem cell face lift technology and expands stem cell collection network into New
Rating: (out of reviews)
List Price: $ 9.95
Price: $ 9.95
When people think of the word ‘cloning’ they are often hit with frightening images of duplicate human beings being created in somewhat of a mad scientist style experiment. In fact, many members of the public were outraged when Dolly the sheep resulted from a cloning experiment in Scotland. Therapeutic cloning, however, is entirely different and does not involve the creation of a perfectly copied human being. It is reproductive cloning that results in a copy of a specific human being. In therapeutic cloning, no sperm fertilisation is involved nor is there implantation into the uterus to create a child.
.
Therapeutic cloning is another phrase for a procedure known as somatic cell nuclear transfer (SCNT). In this procedure, a researcher extracts the nucleus from an egg. The nucleus holds the genetic material for a human or laboratory animal. Scientists then take a somatic cell, which is any body cell other than an egg or sperm, and also extract the nucleus from this cell. In practical human applications, the somatic cell would be taken from a patient who requires a stem cell transplant to treat a health condition or disease.
The nucleus that is extracted from the somatic cell in the patient is then inserted into the egg, which had its nucleus previously removed. In a very basic sense, it’s a procedure of substitution. The egg now contains the patient’s genetic material, or instructions. It is stimulated to divide and shortly thereafter forms a cluster of cells known as a blastocyst. This blastocyst has both an outer and inner layer of cells and it is the inner layer, called the inner cell mass that is rich in stem cells. The cells in the inner cell mass are isolated and then utilised to create embryonic stem cell lines, which are infused into the patient where they are ideally integrated into the tissues, imparting structure and function as needed.
.
A major benefit of therapeutic cloning is that the cells removed are pluripotent.
Pluripotent cells can give rise to all cells in the body with the exception of the embryo. This means that pluripotent cells can potentially treat diseases in any body organ or tissue by replacing damaged and dysfunctional cells. Another distinct advantage to this type of therapy is that the risk of immunological rejection is alleviated because the patient’s own genetic material is used. If a cell line were created with cells from another individual, the patient’s body would be more likely to recognise the foreign proteins and then wage an attack on the transplanted cells. The ultimate consequence would be a rejected stem cell transplant. This is one of the major challenges of organ transplants, alongside the fact that there is a huge shortage of available organs for those who require the procedure. This means that therapeutic cloning has the potential to dramatically reduce the wait times for organ transplants as well as the immunological concerns associated with organ transplant therapy.
Therapeutic cloning is also important to enhancing our understanding of stem cells and how they and other cells develop. This understanding can hopefully lead to new treatments or cures for some of the common diseases affecting people today. In addition, the procedure would allow for scientists to create stem cell therapies that are patient specific and perfectly matched for the patient’s medical condition.
One problem with therapeutic cloning is that many attempts are often required to create a viable egg. The stability of the egg with the infused somatic nucleus is poor and it can require hundreds of attempts before success is attained.
Therapeutic cloning does result in the destruction of an embryo after stem cells are extracted and this destruction has stirred controversy over the morality of the procedure. Some argue that the pros outweigh the cons with regards to treating disease whilst others have likened the destruction to an abortion. Still others state that this doesn’t change the fact the embryo could potentially be a human being and so destruction of the embryo is no different than destruction of a human life.
Because reproductive cloning does utilise SCNT as the primary step, there is also still fear that given our knowledge base to perform reproductive cloning, a scientist may attempt to move beyond therapeutic cloning to creation of a human being.
To this date, no human being has been successfully cloned but the possibility of this occurring is a frightening one not only for the general public and policy makers, but also for most of the ethical scientific field. The majority of scientists are adamantly opposed to reproductive cloning and instead, support therapeutic cloning for treating disease. With policies and careful monitoring in place to ensure that therapeutic cloning is used responsibly, we can all benefit from the potential of this procedure to eventually treat, or perhaps one day cure, many diseases.
Leading pharmaceutical and biotech companies are drawing on Singapore’s integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia with a population base that is representative of key Asian ethnic groups, Singapore provides a home-base of innovation for companies to test and develop new solutions for Asia and beyond.
Recent announcements of public-private partnerships (PPP) include GlaxoSmithKline Biologicals committing US$1.3 million in vaccine and process development with Singapore’s Bioprocessing Technology Institute (BTI); Lilly Singapore Centre for Drug Discovery (LSCDD) teaming up with Singapore’s National Neuroscience Institute (NNI), and the Singapore Institute for Clinical Sciences (SICS) to advance drug discovery using adult brain tumor stem cells.
AstraZeneca announced its collaboration with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) in pre-clinical and clinical development activities of anti-cancer compounds to build up AstraZeneca’s drug development capabilities in Asia; Singapore Immunology Network (SIgN) partnered European biotechs – Humalys SAS and Cytos Biotechnology Ltd – to develop antibodies for combating and managing viruses prevalent in Asia including hand, foot and mouth disease.
Massachusetts-based biotech, FORMA Therapeutics, has also set up its first overseas lab in Singapore’s Nanyang Technological University (NTU). An emerging biotech company, Forma seeks to integrate important new advances in biology and chemistry to unlock the best targets and pathways that genomic medicine has revealed. FORMA will be collaborating with the Experimental Therapeutics Centre of Singapore (ETC) to co-discover novel therapeutics.
“There is no doubt Asia will soon be the next centre of gravity for the global pharma industry. While the diverse Asian market presents tremendous opportunities, it remains challenging to navigate the region’s complexities and harness its opportunities. Singapore provides one of the best locations in Asia, which would enable us to conduct our targeted research, collaborate with public institutions and tap into regional capabilities to supplement our activities,” said Dr Steven Tregay, Chief Executive Officer, FORMA Therapeutics.
Public-Sector Resources Allow for End-to-End Research Activities
As companies worldwide seek to develop new therapies and diagnostics to expand their pipeline of innovative products, PPPs represent an effective way for companies to enhance their R&D productivity and accelerate commercialisation efforts.
Singapore’s advanced research infrastructure, base of more than 2,800 public sector researchers and business-friendly economic policies are fuelling the rapid growth of PPPs in biomedical sciences. Companies may leverage on Singapore’s extensive resources and cross-institutional capabilities to handle complex bench-to-bed and bed-to-bench translational projects. These resources include dedicated clinical bio-imaging research, bio-safety, and early-phase trial facilities. Companies can also tap into the preclinical predictive disease models and platform technologies in genomics and bio-imaging available in Singapore.
Mr. Yeoh Keat Chuan, Executive Director, Biomedical Sciences, Singapore Economic Development Board (EDB) said: “The EDB provides a one-stop shop to link companies to our integrated network of public-sector research and medical institutes. Singapore is also strategically located at the heart of Asia, which makes us an ideal control tower to oversee R&D activities across the heterogeneous landscape in Asia, especially in translational medicine and Asian diseases. Coupled with our pro-business policies and focused efforts to be future-ready, Singapore is well-positioned to be a strategic research partner for the industry and a home-base for innovation in Asia.”
Singapore’s Biopolis: Asian Home-Base for R&D
The Biopolis, a 2.4 million square-foot research campus, is the icon of Singapore’s success in biomedical sciences. Co-locating global companies’ research operations with publicly funded research institutes, the Biopolis is imbued with a campus spirit to advance science and human healthcare via cross- disciplinary, public-private collaborations.
In recognition of this significant advantage, numerous companies have chosen to set up their Asian R&D operations at the Biopolis. Emerging biotech companies such as PharmaLogicals and SGAUSTRIA (formerly Austrianova) are located alongside leading pharmaceutical companies. A 400,000 square-foot Phase 2 expansion of the Biopolis launched in 2006 is already fully subscribed. Another 440,000 square feet of research space is being added and will be ready by 2010.
OKLAHOMA CITY (AP) – A total of $5.5 million from the Tobacco Settlement Endowment Trust will be given for adult stem cell research.
The trust board voted yesterday to make the contributions after hearing presentations about such research that is ongoing in Oklahoma.
Under the plan, the board will give $500,000 for a yearlong planning phase to determine how the money should be distributed, then award $1 million in grants each year for five years.
Dr. Stephen Prescott, the president of the Oklahoma Medical Research Foundation, says adult stem cells have the potential to treat ailments including cancer, cardiovascular disease and diabetes.
He says OMRF scientists are researching how to “back up” progression of adult cells, so that the cells can be reprogrammed for specific uses.
Adult stem cells are not taken from embryos.
Information from: The Oklahoman, http://www.newsok.com
AdultStemCell.com is Stephen Fry proof thanks to caching by WP Super Cache